| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0264-410X(03)00203-2 |
| P698 | PubMed publication ID | 12763687 |
| P50 | author | Cornelia Speth | Q87723630 |
| Heribert Stoiber | Q96068701 | ||
| P2093 | author name string | Manfred P Dierich | |
| P2860 | cites work | Molecular cloning and characterization of the human anaphylatoxin C3a receptor | Q24311767 |
| Mechanism of human immunodeficiency virus-induced complement expression in astrocytes and neurons | Q24537408 | ||
| Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41 | Q24675546 | ||
| Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection | Q28237240 | ||
| Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins | Q28257632 | ||
| The chemotactic receptor for human C5a anaphylatoxin | Q28280054 | ||
| Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes | Q33795645 | ||
| Complement components of the innate immune system in health and disease in the CNS. | Q33974402 | ||
| The supportive role of complement in HIV pathogenesis | Q34287013 | ||
| The envelope glycoprotein of HIV-1 gp120 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology. | Q34291052 | ||
| Neuroinvasion by pathogens: a key role of the complement system | Q34540763 | ||
| Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59 | Q35763321 | ||
| Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1 | Q36365174 | ||
| Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). | Q36366046 | ||
| B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells | Q36368837 | ||
| Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. | Q36831191 | ||
| A neuronal C5a receptor and an associated apoptotic signal transduction pathway | Q38337497 | ||
| Microanatomy of lymphoid tissue during humoral immune responses: structure function relationships | Q38624504 | ||
| Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. | Q39593041 | ||
| Human immunodeficiency virus type 1 induces expression of complement factors in human astrocytes | Q39610112 | ||
| Transcriptional regulation of complement genes | Q40444867 | ||
| A "complement-ary" AIDS vaccine | Q40953980 | ||
| Complement C5a anaphylatoxin fragment causes apoptosis in TGW neuroblastoma cells | Q41019307 | ||
| Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis | Q41027043 | ||
| Acquisition of host cell-surface-derived molecules by HIV-1. | Q41148414 | ||
| Expression of complement in the brain: role in health and disease | Q41203060 | ||
| Extrahepatic complement biosynthesis: where, when and why? | Q41331539 | ||
| Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement | Q41404377 | ||
| Role of complement in HIV infection | Q41464367 | ||
| Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV. | Q41536475 | ||
| Germinal centre CD4+ T cells are an important site of HIV replication in vivo. | Q44588643 | ||
| Follicular dendritic cells and human immunodeficiency virus infectivity | Q45080369 | ||
| Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy | Q45745464 | ||
| Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry? | Q45757965 | ||
| Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1. | Q46769983 | ||
| Quantitative image analysis of HIV-1 infection in lymphoid tissue | Q49118200 | ||
| Activation of HIV gene expression during monocyte differentiation by induction of NF-kB | Q59073190 | ||
| Complement 5a controls motility of murine microglial cells in vitro via activation of an inhibitory G-protein and the rearrangement of the actin cytoskeleton | Q71538959 | ||
| HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology | Q71570064 | ||
| Direct Interaction of Complement Factor H with the C1 Domain of HIV Type 1 Glycoprotein 120 | Q71783860 | ||
| HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells | Q72092354 | ||
| B cell-mediated infection of stimulated and unstimulated autologous T lymphocytes with HIV-1: role of complement | Q73111991 | ||
| Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system | Q73471627 | ||
| C5a and C5a(desArg) enhance the susceptibility of monocyte-derived macrophages to HIV infection | Q73509961 | ||
| B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1 | Q77419360 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | S77-82 | |
| P577 | publication date | 2003-06-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Role of complement in the control of HIV dynamics and pathogenesis | |
| P478 | volume | 21 Suppl 2 |
| Q34749137 | A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS |
| Q33290541 | Absence of erythrocyte-associated HIV-1 in vivo |
| Q45877055 | Bioluminescence imaging reveals a significant role for complement in liver transduction following intravenous delivery of adenovirus |
| Q33804431 | Complement Evasion Strategies of Viruses: An Overview |
| Q34610122 | Complement and HIV-I infection/HIV-associated neurocognitive disorders |
| Q28766705 | Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection |
| Q40706471 | Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD). |
| Q33834852 | Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection |
| Q33955105 | Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization |
| Q44916240 | Elevated B-cell autoantibodies among HIV+ transplant candidates: crossmatch implications |
| Q40657302 | Glycosylphosphatidylinositol Anchor Deficiency Attenuates the Production of Infectious HIV-1 and Renders Virions Sensitive to Complement Attack |
| Q35988809 | HIV-1 and the hijacking of dendritic cells: a tug of war. |
| Q35096836 | HIV-1-specific antibody responses during acute and chronic HIV-1 infection |
| Q73430060 | INNAMORA, a European Workshop focussed on the mechanisms of innate immunity in pathogen-host interaction and their exploitation in novel mucosal immunisation strategies |
| Q30447940 | Identification of complement regulatory domains in vaccinia virus complement control protein |
| Q40377124 | Immune deficiency in HIV-1 infection: novel therapeutic approaches targeting innate and adaptive responses |
| Q37348541 | Kinetic analysis of the interactions between vaccinia virus complement control protein and human complement proteins C3b and C4b. |
| Q37109384 | Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells. |
| Q37189179 | Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease |
| Q40061486 | Plasma levels of complement factor I and C4b peptides are associated with HIV suppression |
| Q97533707 | Plasma proteomics reveals markers of metabolic stress in HIV infected children with severe acute malnutrition |
| Q36540060 | Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked |
| Q39265150 | Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques |
| Q36670538 | Role of IL-21 and IL-21 receptor on B cells in HIV infection |
| Q35055116 | Scaffold functions of 14-3-3 adaptors in B cell immunoglobulin class switch DNA recombination |
| Q28275986 | The good and evil of complement activation in HIV-1 infection |
Search more.